- Home
- HCKT vs XNCR Comparison
HCKT vs XNCR Comparison
Compare HCKT & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCKT | XNCR |
|---|---|---|
| Founded | 1991 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.5M | 2.0B |
| IPO Year | 1998 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HCKT | XNCR |
|---|---|---|
| Price | $10.77 | $25.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $16.67 | ★ $31.42 |
| AVG Volume (30 Days) | 182.0K | ★ 1.1M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.45% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $285,862,000.00 | $125,576,000.00 |
| Revenue This Year | N/A | $14.05 |
| Revenue Next Year | $3.57 | N/A |
| P/E Ratio | $32.26 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $9.16 | $10.38 |
| 52 Week High | $20.68 | $30.61 |
Technical Indicators
Market Signals| Indicator | HCKT | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 53.78 |
| Support Level | $10.48 | $23.33 |
| Resistance Level | $11.59 | $30.61 |
| Average True Range (ATR) | 0.37 | 1.06 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 66.30 | 68.29 |
Price Performance
Historical ComparisonAbout HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.